



**Investor Relations:**

Marty Tullio, Managing Partner  
McCloud Communications, LLC  
949.553.9748  
[marty@mccloudcommunications.com](mailto:marty@mccloudcommunications.com)

**CNS Response Expands Its Technology to Fort Belvoir  
-Walter Reed Continues Treating Soldiers-**

**Aliso Viejo, Calif., May 10, 2013 – CNS Response, Inc. (OTCBB: CNSO)** today announced that it has opened a second site for its PEER Interactive trial at Fort Belvoir Community Hospital in Virginia, one of the Army’s largest treatment facilities for active military personnel. Fort Belvoir is the second military site to participate under an approved, 2,000-soldier protocol and Cooperative Research and Development Agreement.

PEER Interactive builds evidence for mental health treatments, an area where there has traditionally been no physiological test to help physicians individualize prescriptions for their patients, and treatments fail frequently. PEER correlates a reliable, well-normed test of brain function (EEG) with a published physician outcome registry (PEER). A growing body of evidence -- 75 studies on PEERDossier.com -- has shown reduced trial and error prescribing, and health outcomes that are two times better than treatment as usual when using PEER Interactive technology.

**About CNS Response**

CNS Response provides reference data and analytic tools for clinicians and researchers in psychiatry. Treatment for mental disorders has doubled in the last 20 years, and use of medications has grown over 400% -- but treatments fail more often than they succeed and over 17 million Americans have failed two or more medication therapies for their mental disorder. The company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the company’s original physician-developed database, there are now more than 35,000 outcomes for 8,700 unique patients in the PEER registry. The objective of PEER Online is to avoid trial and error pharmacotherapy, the dominant approach for treatment resistant patients.

To read more about the benefits of this patented technology for patients, physicians and payers, please visit [www.cnsresponse.com](http://www.cnsresponse.com). Medical professionals interested in learning more can contact CNS Response at [PEERinfo@cnsresponse.com](mailto:PEERinfo@cnsresponse.com).

**Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995**

*Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company’s filings with the Securities and Exchange*

*Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.*

*###*